News | Cath Lab | February 27, 2019

DABRA Excimer Laser System Demonstrates Success in Treating PAD

Study achieved a statistically significant difference in pre- and post-percent stenosis and ankle-brachial index values

DABRA Excimer Laser System Demonstrates Success in Treating PAD

February 27, 2019 — Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s DABRA System for the treatment of above- and below-the-knee peripheral artery disease (PAD). The data was presented by Ashok Kondur, M.D., FACC, FSCAI at the 2019 Leipzig Interventional Course (LINC) in Leipzig, Germany.

The study results were overwhelmingly positive, according to the company, given the inclusion of a challenging sample of patients, all Rutherford class 4 to 6 with a high presence of calcium (80 percent of lesions had moderate to severe calcification) and 93 percent median lesion stenosis. A statistically significant difference was demonstrated in pre- and post-diameter stenosis (p<0.001), and lesion success, defined as <30 percent post diameter stenosis, was 98 percent. Furthermore, the results demonstrated statistically significant improvements in limb hemodynamic measures.

“The results of this study are extremely promising and demonstrate the positive clinical outcomes we have seen with DABRA,” said Kondur, chair, Division of Cardiology, Garden City Hospital/MSU and associate program director, Interventional Cardiology Fellowship Program, DMC Harper University Hospital, Wayne State University.

The purpose of the study was to evaluate the use of DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) in patients with above-the-knee and below-the-knee disease in a cohort of 52 patients and 111 collective lesions. Patients were treated solely with DABRA plus percutaneous coronary angioplasty (PTA), with no adjunctive stenting. Intravascular ultrasound and/or angiography was used pre- and post-treatment.

“We have seen significant changes in pre- and post-ABIs [ankle-brachial indices] and a very low complication rate with no distinct clinically or angiographically observed distal embolization,” said study lead investigator Elias Kassab, M.D., FACC, FSCAI, FACP, FASA, RPVI, FAHA, FSVM, president and CEO of Michigan Outpatient Vascular Institute and assistant professor of medicine, Wayne State University.

DABRA is a safe, versatile and simple catheter and laser system for the treatment of mixed morphology vascular blockages above- and below-the-knee. Its photochemical plaque ablating mechanism of action reduces all plaque types (calcium, thrombus and atheroma) into their fundamental chemistry with reduced mechanical, thermal and barometric trauma and minimized downstream debris.

The positive results presented at LIN 2019 are reaffirmed by Athar Ansari, M.D., DTM&H, MRCP, FACC, in his case report, Treatment of a Long, Heavily Calcified left SFA Lesion with Single-Vessel Runoff Via an Ipsilateral Antegrade Approach, published in the January issue of Endovascular Today. In the article, Ansari highlights the product’s fast and easy use with no distal embolization in yet another challenging case.

For more information: www.ramed.com


Related Content

News | ACC

June 1, 2023 — The American College of Cardiology will host the annual Care of the Athletic Heart course on June 8-10 ...

Home June 01, 2023
Home
News | ACC

May 26, 2023 — The Clinical Hospital of Emergency Services, a municipal hospital serving the community of Dnipro, in ...

Home May 26, 2023
Home
News | ACC

April 11, 2023 — A newly-published study in the Journal of the American College of Cardiology, JACC, the flagship ...

Home April 11, 2023
Home
News | ACC

March 21, 2023 — As part of its extensive coverage, the editorial team at dicardiology.com/DAIC has shared summary ...

Home March 21, 2023
Home
News | ACC

March 16, 2023 — The American College of Cardiology (ACC) announced the winners and finalists of its 2023 Young ...

Home March 16, 2023
Home
News | ACC

March 12, 2023 — As part of its ongoing news coverage of ACC23, the DAIC/dicardiology.com editorial team has condensed ...

Home March 12, 2023
Home
News | ACC

March 9, 2023 — C. Noel Bairey Merz, MD, FACC, professor of cardiology and the director of the Barbra Streisand Women’s ...

Home March 09, 2023
Home
News | ACC

March 9, 2023 — Positive results from a Mineralys Therapeutics study, the Target-HTN Phase 2 trial, demonstrated ...

Home March 09, 2023
Home
News | ACC

March 8, 2023 — B. Hadley Wilson, MD, FACC, is the new president of the American College of Cardiology. Today marks the ...

Home March 08, 2023
Home
News | ACC

March 6, 2023 — In findings presented from the STELLAR Phase III Trial during the American College of Cardiology’s 2023 ...

Home March 06, 2023
Home
Subscribe Now